Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Metrics to compare | CGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCGTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.3x | −0.5x | −0.6x | |
PEG Ratio | −0.20 | 0.10 | 0.00 | |
Price/Book | 29.4x | 2.3x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.3x | |
Upside (Analyst Target) | 24.6% | 153.9% | 38.0% | |
Fair Value Upside | Unlock | 9.3% | 4.4% | Unlock |